Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER

Optimizing systolic blood pressure (SBP) in heart failure (HF) with preserved ejection fraction carries a Class I recommendation but with limited evidence. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have antihypertensive effects across cardiovascular disease. The authors examined the interpla...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JACC. Heart failure 2023-01, Vol.11 (1), p.76-89
Hauptverfasser:	Selvaraj, Senthil, Vaduganathan, Muthiah, Claggett, Brian L, Miao, Zi Michael, Fang, James C, Vardeny, Orly, Desai, Akshay S, Shah, Sanjiv J, Lam, Carolyn S P, Martinez, Felipe A, Inzucchi, Silvio E, de Boer, Rudolf A, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J V, Solomon, Scott D
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Benzhydryl Compounds - pharmacology Benzhydryl Compounds - therapeutic use Blood Pressure - physiology Female Heart Failure Humans Male Middle Aged Stroke Volume - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Optimizing systolic blood pressure (SBP) in heart failure (HF) with preserved ejection fraction carries a Class I recommendation but with limited evidence. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have antihypertensive effects across cardiovascular disease. The authors examined the interplay between SBP and treatment effects of dapagliflozin on SBP and cardiovascular outcomes. The authors analyzed 6,263 DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) participants and related baseline and mean achieved SBP categories (
ISSN:	2213-1787
DOI:	10.1016/j.jchf.2022.09.002